Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Merck to discontinue development of EMR-62203

March 29, 2004

Fosrenol receives approval in Sweden

March 26, 2004

NM-100061 produces positive results in early ejaculation study

March 25, 2004

Antares' topical oxybutynin product successfully completes phase I trial

March 19, 2004

Milestone achievements and patient treatment with Prolieve

March 16, 2004

GSK presents four related series of ALK5 inhibitors

March 16, 2004

Nippon Kayaku reports in vivo effects of NK-082411 on micturition

March 12, 2004

Patient, physician satisfaction with Levitra

March 12, 2004

Four new SOAR collaborations for KRX-101

March 12, 2004

Nippon Shinyaku and Seikagaku terminate NS-7201 license agreement

March 9, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...